Keywords: Hemispherx Biopharma, Ampligen, USA, FDA, CRL, Chronic fatigue syndrome

FDA gives Hemispherx time to respond to CRL

Article | 12 January 2012

Print This

Shares of USA-based Hemispherx Biopharma (NYSE Amex: HEB) rose 14% to $0.24 on Wednesday, after the company announced that the Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in